Focuses on the Consolidation for Leading Projects
Accelerates Clinical Trials for Core Products STP705, STP707 and STP122G
HONG KONG, Germantown, Md. and SUZHOU, China, March 28, 2024 /PRNewswire/.
Positive Clinical Readouts Validate Potential of Proprietary Delivery Platforms and Cement Global Leadership in RNAi Therapeutics Business Highlights Promising.